Skip to main content
main-content

06-06-2022 | ASCO 2022 | Conference coverage | Video

ATLANTIS rules out cabozantinib as a maintenance option for mUC

share
SHARE

Robert Jones explains why the ATLANTIS trial findings do not support the use of single-agent cabozantinib for the maintenance treatment of metastatic urothelial carcinoma, and what they mean for the role of VEGFR-targeted therapies in this tumor type (3:23).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

2022 ASCO Annual Meeting coverage

Access the latest news and expert insight from the 2022 ASCO Annual Meeting

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.